Drug Profile
Lasmiditan - CoLucid Pharmaceuticals
Alternative Names: COL-144; LY-573144Latest Information Update: 04 Apr 2018
Price :
*
At a glance
- Originator Eli Lilly; Lundbeck A/S
- Developer CoLucid Pharmaceuticals; Eli Lilly
- Class Antimigraines; Benzamides; Piperidines; Pyridines; Small molecules
- Mechanism of Action Serotonin 1F receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Migraine
Most Recent Events
- 26 Mar 2018 Eli Lilly initiates a phase I trial in Healthy volunteers in USA (PO) (NCT03459612)
- 15 Mar 2018 Eli Lilly plans a phase I trial in Healthy volunteers in USA in March 2018 (PO) (NCT03459612)
- 22 Jan 2018 Phase-I clinical trials in Migraine (In the elderly, In volunteers) in USA (PO) (NCT03406260)